BR9912501A - Tratamento de distúrbios hiperproliferativos - Google Patents
Tratamento de distúrbios hiperproliferativosInfo
- Publication number
- BR9912501A BR9912501A BR9912501-3A BR9912501A BR9912501A BR 9912501 A BR9912501 A BR 9912501A BR 9912501 A BR9912501 A BR 9912501A BR 9912501 A BR9912501 A BR 9912501A
- Authority
- BR
- Brazil
- Prior art keywords
- inhibitor
- ceramide
- treatment
- preferred
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/15—Suppositories
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Patente de Invenção: <B>"TRATAMENTO DE DISTúRBIOS HIPERPROLIFERATIVOS"<D>. Método para tratamento de um distúrbio hiperproliferativo em um indivíduo necessitando deste tratamento, compreendendo a administração ao referido indivíduo, em combinação, de uma quantidade eficiente de um tratamento com: (a) um retinóide gerador de ceramida, como a fenretinida, ou um sal farmaceuticamente aceitável da mesma; e (b) pelo menos um (e, em certas modalidades, pelo menos dois) inibidor de degradação da ceramida, como os compostos selecionados do grupo que consiste em (i) inibidores de síntese de glicosilceramida, (ii) inibidores de síntese de esfingosina-1-fosfato, e (iii) inibidores de quinase da proteína C. Um inibidor de síntese de glicosilceramida preferido é o 1-fenil-2-palmitoilamino-3-morfolino-1-propanol. Um inibidor de síntese de esfingosina-1-fosfato preferido é D-eritro-N, N-dimetilesfingosina. Um inibidor de quinase de proteína C preferido é L-treo-dihidroesfingosina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9113898P | 1998-06-29 | 1998-06-29 | |
PCT/US1999/014591 WO2000000207A1 (en) | 1998-06-29 | 1999-06-28 | Treatment of hyperproliferative disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9912501A true BR9912501A (pt) | 2001-05-02 |
Family
ID=22226266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9912501-3A BR9912501A (pt) | 1998-06-29 | 1999-06-28 | Tratamento de distúrbios hiperproliferativos |
Country Status (12)
Country | Link |
---|---|
US (1) | US6352844B1 (pt) |
EP (1) | EP1091745B1 (pt) |
JP (1) | JP4965764B2 (pt) |
CN (1) | CN100358529C (pt) |
AT (1) | ATE409486T1 (pt) |
AU (1) | AU4724599A (pt) |
BR (1) | BR9912501A (pt) |
CA (1) | CA2335941C (pt) |
DE (1) | DE69939651D1 (pt) |
DK (1) | DK1091745T3 (pt) |
ES (1) | ES2316188T3 (pt) |
WO (1) | WO2000000207A1 (pt) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6098631A (en) * | 1998-01-21 | 2000-08-08 | The Regents Of The University Of Michigan | Compositions and methods for treating autoimmune disease |
US6368831B1 (en) * | 1998-06-29 | 2002-04-09 | Childrens Hospital Los Angeles | Treatment of hyperproliferative disorders |
GB0006539D0 (en) * | 2000-03-17 | 2000-05-10 | Oxford Glycosciences Uk Ltd | Therapies |
AUPQ744700A0 (en) * | 2000-05-11 | 2000-06-01 | Medvet Science Pty. Ltd. | A method of treatment and agents useful for same |
EP1195604A1 (en) * | 2000-09-29 | 2002-04-10 | Warner-Lambert Company | Methods and compositions for screening modulators of lipid kinases |
JP4384409B2 (ja) | 2000-12-05 | 2009-12-16 | チルドレンズ・ホスピタル・ロス・アンジエルス | バイオアベイラビリティが増加したフェンレチニドの医薬組成物、およびその使用方法 |
EP1363643A2 (en) * | 2000-12-22 | 2003-11-26 | Medlyte, Inc. | Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor |
US20040097587A1 (en) * | 2002-03-27 | 2004-05-20 | Arbiser Jack L | Compositions and methods of treatment of ulcerating diseases, burns, and related conditions |
US20030226181P1 (en) * | 2002-05-31 | 2003-12-04 | Mason Harleigh C. | Apple tree named 'Rosy Glow' |
JP3405981B1 (ja) * | 2002-06-26 | 2003-05-12 | 日本財経株式会社 | 酢酸セルロースの製造方法 |
CA2499523C (en) * | 2002-09-20 | 2011-04-19 | Medisyn Technologies, Inc. | Therapeutic agents and corresponding treatments |
US7785621B2 (en) * | 2003-01-31 | 2010-08-31 | Childrens Hospital Los Angeles | Oral compositions of fenretinide having increased bioavailability and methods of using the same |
EP1594488B1 (en) * | 2003-02-21 | 2006-06-28 | Childrens Hospital of Los Angeles Research Institute | Stabilized pharmaceutical compositions of safingol and methods of using the same |
US20050101674A1 (en) * | 2003-11-12 | 2005-05-12 | Maurer Barry J. | PPMP as a ceramide catabolism inhibitor for cancer treatment |
US20070258970A1 (en) * | 2003-12-09 | 2007-11-08 | Robert Blumenthal | Methods for Inhibiting Hiv and Other Viral Infections by Modulating Ceramide Metabolism |
CA2558429C (en) | 2004-03-02 | 2011-02-01 | Mcgill University | Compositions and methods for preventing or treating an inflammatory response |
US7794713B2 (en) * | 2004-04-07 | 2010-09-14 | Lpath, Inc. | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
WO2005123055A2 (en) * | 2004-06-14 | 2005-12-29 | Musc Foundation For Research Development | Methods for treating inflammatory disorders |
CN101022803B (zh) * | 2004-07-09 | 2011-11-23 | 药物合成技术公司 | 治疗化合物和治疗 |
CA2581061C (en) * | 2004-10-28 | 2014-09-02 | Lpath Therapeutics, Inc. | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
US20060257493A1 (en) * | 2005-04-28 | 2006-11-16 | Amiji Mansoor M | Nanoparticulate delivery systems for treating multi-drug resistance |
US20090074720A1 (en) * | 2005-10-28 | 2009-03-19 | Sabbadini Roger A | Methods for decreasing immune response and treating immune conditions |
US20080213274A1 (en) * | 2005-10-28 | 2008-09-04 | Sabbadini Roger A | Compositions and methods for the treatment and prevention of fibrotic, inflammatory, and neovascularization conditions of the eye |
NZ572601A (en) | 2006-03-29 | 2012-03-30 | Univ Wayne State | Liposomal nanoparticles and other formulations of fenretinide for use in therapy and drug delivery |
US7862812B2 (en) * | 2006-05-31 | 2011-01-04 | Lpath, Inc. | Methods for decreasing immune response and treating immune conditions |
US9217749B2 (en) * | 2006-05-31 | 2015-12-22 | Lpath, Inc. | Immune-derived moieties reactive against lysophosphatidic acid |
US8796429B2 (en) * | 2006-05-31 | 2014-08-05 | Lpath, Inc. | Bioactive lipid derivatives, and methods of making and using same |
US9274130B2 (en) | 2006-05-31 | 2016-03-01 | Lpath, Inc. | Prevention and treatment of pain using antibodies to lysophosphatidic acid |
US9274129B2 (en) * | 2006-05-31 | 2016-03-01 | Lpath, Inc. | Methods and reagents for detecting bioactive lipids |
AU2007313822A1 (en) * | 2006-10-27 | 2008-05-08 | Lpath, Inc. | Compositions and methods for treating ocular diseases and conditions |
CA2667574A1 (en) | 2006-10-27 | 2008-06-12 | Roger A. Sabbadini | Compositions and methods for binding sphingosine-1-phosphate |
WO2009045345A1 (en) * | 2007-09-28 | 2009-04-09 | Childrens Hospital Los Angeles Research Institute | Metabolic degradation inhibitors for anti-hyperproliferative agents |
US8361465B2 (en) * | 2007-10-26 | 2013-01-29 | Lpath, Inc. | Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents |
GB0803352D0 (en) | 2008-02-22 | 2008-04-02 | Ntnu Technology Transfer As | Oligopeptidic compounds and uses thereof |
US20090253733A1 (en) * | 2008-04-02 | 2009-10-08 | Biointeractions, Ltd. | Rapamycin carbonate esters |
US8088822B2 (en) * | 2008-07-08 | 2012-01-03 | Ji Zhang | Use of fenretinide or bioactive derivatives thereof and pharmaceutical compositions comprising the same |
CN101623277B (zh) * | 2008-07-08 | 2014-07-16 | 上海交通大学医学院附属瑞金医院 | 芬维a胺及其活性衍生物的新用途及其药物组合物 |
US8871202B2 (en) | 2008-10-24 | 2014-10-28 | Lpath, Inc. | Prevention and treatment of pain using antibodies to sphingosine-1-phosphate |
CN102892748A (zh) * | 2009-11-12 | 2013-01-23 | 德克萨斯理工大学 | 用于治疗过度增生性疾病的组合物和方法 |
WO2011140296A1 (en) * | 2010-05-05 | 2011-11-10 | Infinity Pharmaceuticals | Triazoles as inhibitors of fatty acid synthase |
WO2012068169A2 (en) * | 2010-11-15 | 2012-05-24 | Texas Tech University | Substance for increasing the production of a specific acyl-chain dihydroceramide(s) for improving the effectiveness of cancer treatments |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4190594A (en) | 1975-11-03 | 1980-02-26 | Johnson & Johnson | Retinoic acid derivatives |
US4323581A (en) | 1978-07-31 | 1982-04-06 | Johnson & Johnson | Method of treating carcinogenesis |
US4665098A (en) | 1985-03-28 | 1987-05-12 | Mcneilab, Inc. | Pharmaceutical composition of N-(4-hydroxyphenyl) retinamide having increased bioavailability |
US4816450A (en) * | 1986-09-15 | 1989-03-28 | Duke University | Inhibition of protein kinase C by long-chain bases |
US5041441A (en) | 1988-04-04 | 1991-08-20 | The Regents Of The University Of Michigan | Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol |
US5190876A (en) * | 1988-12-27 | 1993-03-02 | Emory University | Method of modifying cellular differentiation and function and compositions therefor |
EP0671953A4 (en) | 1992-11-13 | 1996-01-10 | Univ Ohio State Res Found | ANALOGS OF N- (4-HYDROXYPHENYL) RETINAMIDE-O-GLUCURONIDE ARYLAMIDE. |
US5302609A (en) | 1992-12-16 | 1994-04-12 | The Regents Of The University Of Michigan | Treatment of diabetic nephropathy |
US5464870A (en) | 1993-02-10 | 1995-11-07 | Ortho Pharmaceutical Corporation | Methods of inhibiting development of leukoplakia with fenretinide |
JP3778926B2 (ja) | 1993-08-13 | 2006-05-24 | 生化学工業株式会社 | 神経疾患治療剤 |
US5635536A (en) | 1994-12-07 | 1997-06-03 | Pharmacia & Upjohn Aktiebolag | Emulsion suitable for administering a sphingolipid |
US5821254A (en) * | 1995-02-17 | 1998-10-13 | The United States Of America As Represented By The Department Of Health And Human Services | Uses of 9-cis-retinoic acids and derivatives thereof alone or in combination with antineoplastic agents in the prevention or treatment of cancer |
US6245805B1 (en) * | 1995-10-26 | 2001-06-12 | Baker Norton Pharmaceuticals, Inc. | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
JPH09176083A (ja) | 1995-12-28 | 1997-07-08 | Sankyo Co Ltd | 新規化合物f−12509a |
US5821072A (en) | 1996-02-20 | 1998-10-13 | Sloan-Kettering Institute For Cancer Research | Combinations of PKC inhibitors and therapaeutic agents for treating cancers |
US5885786A (en) | 1996-04-19 | 1999-03-23 | John Wayne Cancer Institute | Methods for screening of substances for inhibition of multidrug resistance |
-
1999
- 1999-06-28 US US09/342,019 patent/US6352844B1/en not_active Expired - Lifetime
- 1999-06-28 CA CA2335941A patent/CA2335941C/en not_active Expired - Lifetime
- 1999-06-28 ES ES99930790T patent/ES2316188T3/es not_active Expired - Lifetime
- 1999-06-28 EP EP99930790A patent/EP1091745B1/en not_active Expired - Lifetime
- 1999-06-28 BR BR9912501-3A patent/BR9912501A/pt not_active IP Right Cessation
- 1999-06-28 JP JP2000556792A patent/JP4965764B2/ja not_active Expired - Lifetime
- 1999-06-28 CN CNB998081426A patent/CN100358529C/zh not_active Expired - Fee Related
- 1999-06-28 AT AT99930790T patent/ATE409486T1/de not_active IP Right Cessation
- 1999-06-28 DK DK99930790T patent/DK1091745T3/da active
- 1999-06-28 WO PCT/US1999/014591 patent/WO2000000207A1/en active Application Filing
- 1999-06-28 DE DE69939651T patent/DE69939651D1/de not_active Expired - Lifetime
- 1999-06-28 AU AU47245/99A patent/AU4724599A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP4965764B2 (ja) | 2012-07-04 |
EP1091745A4 (en) | 2003-08-27 |
JP2002519329A (ja) | 2002-07-02 |
ES2316188T3 (es) | 2009-04-01 |
ATE409486T1 (de) | 2008-10-15 |
US6352844B1 (en) | 2002-03-05 |
EP1091745B1 (en) | 2008-10-01 |
AU4724599A (en) | 2000-01-17 |
CN1308538A (zh) | 2001-08-15 |
EP1091745A1 (en) | 2001-04-18 |
WO2000000207A9 (en) | 2000-05-18 |
DK1091745T3 (da) | 2008-12-15 |
CA2335941C (en) | 2011-03-22 |
WO2000000207A1 (en) | 2000-01-06 |
DE69939651D1 (de) | 2008-11-13 |
CN100358529C (zh) | 2008-01-02 |
CA2335941A1 (en) | 2000-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9912501A (pt) | Tratamento de distúrbios hiperproliferativos | |
PT867184E (pt) | Utilizacao de tiagabina para o tratamento de desordens do sono | |
PT971713E (pt) | Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao | |
BR0008958A (pt) | Inibidores de reabsorção de monoamina para otratamento de distúrbios do snc | |
SE9803710D0 (sv) | Use of certain drugs for treating nerve root injury | |
TR200000755T2 (tr) | Karşıt olma-karşı gelme bozukluğunun tedavisi. | |
DK0699439T3 (da) | Behandling af sygdomme forårsaget af talgkirtellidelser med acyl-CoA-cholesterolacyltransferaseinhibitorer | |
WO2004091540A3 (en) | Methods of treating pain and compositions for use therefor | |
DK0840606T3 (da) | Små di- og trivalente molekyler som selectininhibitorer | |
BR9909872A (pt) | uso de dexmedetomidina para uma unidade de sedação de proteção intensiva | |
RU94044356A (ru) | Применение 2-фенил-3-ароилбензотиофенов для увеличения экспрессии тромбомодулина для ингибирования тромботического расстройства, для увеличения активации протеина с | |
PT1274685E (pt) | Derivado de piridina-n-oxido e processo para a sua transformacao em compostos farmaceuticamente eficazes | |
BRPI0415136A (pt) | método para a diminuição da produção de sebo | |
EA199800866A1 (ru) | Способ снятия боли | |
NZ313076A (en) | Medicament containing duloxetine for treating hyperactivity and attention deficiency disorders | |
DE69406779T2 (de) | 2-substituierte morpholin- und thiomorpholinderivate als gaba-b antagonisten | |
ES2158887T3 (es) | Procedimiento para tratar la prostatitis cronica con 17 beta-n-terc-butilcarbamoil-4-aza-5 alfa-androst-1-en-ona. | |
BR9911150A (pt) | Método de tratamento | |
BR9915899A (pt) | Composto, composição farmacêutica e método para tratar ou inibir distúrbios associados com contração do músculo liso. | |
DK1011672T3 (da) | Anvendelse af (E)-metanicotin derivater til frembringelse af analgetiske virkninger | |
MEP20308A (en) | THE USE OF R(+)-alpha-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL FOR THE TREATMENT OF SLEEP DISORDERS | |
UA26886C2 (uk) | Солі 1,3-діарил-4,5-поліметилеhімідазолію, що виявляють аhальгезуючу активhість | |
ATE293605T1 (de) | Fluorierte 3,4-dihydrochinolin-derivative als nos-inhibitoren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A E 8A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1919 DE 16/10/2007. |